# Workiva Inc: financial statements, quarterly

WK · NYSE · CIK 1445305 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wk.md) · [Financials](/companies/wk/financials.md) · [Filings](/companies/wk/filings.md) · [Insiders](/companies/wk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [158](/filings/0001445305-24-000143.md) | [167 d](/filings/0001445305-26-000016.md) | [176](/filings/0001445305-25-000091.md) | [178](/filings/0001445305-25-000125.md) | [186](/filings/0001445305-25-000142.md) | [200 d](/filings/0001445305-26-000016.md) | [206](/filings/0001445305-26-000045.md) | [215](/filings/0001445305-26-000060.md) | [224](/filings/0001445305-25-000142.md) | [239 d](/filings/0001445305-26-000016.md) | [247](/filings/0001445305-26-000045.md) | [255](/filings/0001445305-26-000060.md) |
| Cost of revenue | $m | [38.4](/filings/0001445305-24-000143.md) | [37.8 d](/filings/0001445305-26-000016.md) | [41.5](/filings/0001445305-25-000091.md) | [41.2](/filings/0001445305-25-000125.md) | [43.7](/filings/0001445305-25-000142.md) | [45.7 d](/filings/0001445305-26-000016.md) | [48.3](/filings/0001445305-26-000045.md) | [49.5](/filings/0001445305-26-000060.md) | [46.4](/filings/0001445305-25-000142.md) | [46.2 d](/filings/0001445305-26-000016.md) | [48.5](/filings/0001445305-26-000045.md) | [50.0](/filings/0001445305-26-000060.md) |
| Gross profit | $m | [120](/filings/0001445305-24-000143.md) | [129 d](/filings/0001445305-26-000016.md) | [134](/filings/0001445305-25-000091.md) | [136](/filings/0001445305-25-000125.md) | [142](/filings/0001445305-25-000142.md) | [154 d](/filings/0001445305-26-000016.md) | [158](/filings/0001445305-26-000045.md) | [166](/filings/0001445305-26-000060.md) | [178](/filings/0001445305-25-000142.md) | [193 d](/filings/0001445305-26-000016.md) | [199](/filings/0001445305-26-000045.md) | [205](/filings/0001445305-26-000060.md) |
| Research and development | $m | [41.7](/filings/0001445305-24-000143.md) | [42.6 d](/filings/0001445305-26-000016.md) | [45.5](/filings/0001445305-25-000091.md) | [48.4](/filings/0001445305-25-000125.md) | [48.4](/filings/0001445305-25-000142.md) | [50.6 d](/filings/0001445305-26-000016.md) | [53.8](/filings/0001445305-26-000045.md) | [54.8](/filings/0001445305-26-000060.md) | [51.4](/filings/0001445305-25-000142.md) | [54.8 d](/filings/0001445305-26-000016.md) | [52.9](/filings/0001445305-26-000045.md) | [57.5](/filings/0001445305-26-000060.md) |
| Operating income | $m | [(15.5)](/filings/0001445305-24-000143.md) | [(9.5) d](/filings/0001445305-26-000016.md) | [(18.3)](/filings/0001445305-25-000091.md) | [(23.1)](/filings/0001445305-25-000125.md) | [(21.8)](/filings/0001445305-25-000142.md) | [(13.3) d](/filings/0001445305-26-000016.md) | [(24.8)](/filings/0001445305-26-000045.md) | [(22.1)](/filings/0001445305-26-000060.md) | [(3.4)](/filings/0001445305-25-000142.md) | [7.9 d](/filings/0001445305-26-000016.md) | [15.3](/filings/0001445305-26-000045.md) | [11.7](/filings/0001445305-26-000060.md) |
| Interest expense | $m | [47.4](/filings/0001445305-23-000166.md) | [3.2 d](/filings/0001445305-24-000021.md) | [3.2](/filings/0001445305-25-000091.md) | [3.2](/filings/0001445305-25-000125.md) | [3.2](/filings/0001445305-25-000142.md) | [3.2 d](/filings/0001445305-26-000016.md) | [3.2](/filings/0001445305-26-000045.md) | [3.2](/filings/0001445305-26-000060.md) | [3.2](/filings/0001445305-25-000142.md) | [3.2 d](/filings/0001445305-26-000016.md) | [3.2](/filings/0001445305-26-000045.md) | [3.2](/filings/0001445305-26-000060.md) |
| Income tax | $m | [0.5](/filings/0001445305-24-000143.md) | [1.5 d](/filings/0001445305-26-000016.md) | [0.7](/filings/0001445305-25-000091.md) | [1.5](/filings/0001445305-25-000125.md) | [1.0](/filings/0001445305-25-000142.md) | [2.5 d](/filings/0001445305-26-000016.md) | [1.9](/filings/0001445305-26-000045.md) | [1.7](/filings/0001445305-26-000060.md) | [(0.6)](/filings/0001445305-25-000142.md) | [0.8 d](/filings/0001445305-26-000016.md) | [1.6](/filings/0001445305-26-000045.md) | [3.3](/filings/0001445305-26-000060.md) |
| Net income | $m | [(56.3)](/filings/0001445305-24-000143.md) | [(4.2) d](/filings/0001445305-26-000016.md) | [(11.7)](/filings/0001445305-25-000142.md) | [(17.5)](/filings/0001445305-25-000142.md) | [(17.0)](/filings/0001445305-25-000142.md) | [(8.8) d](/filings/0001445305-26-000016.md) | [(21.4)](/filings/0001445305-26-000060.md) | [(19.4)](/filings/0001445305-26-000060.md) | [2.8](/filings/0001445305-25-000142.md) | [11.8 d](/filings/0001445305-26-000016.md) | [19.0](/filings/0001445305-26-000060.md) | [13.4](/filings/0001445305-26-000060.md) |
| Diluted EPS | $ per share | [(1.04)](/filings/0001445305-24-000143.md) | not reported | [(0.21)](/filings/0001445305-25-000091.md) | [(0.32)](/filings/0001445305-25-000125.md) | [(0.31)](/filings/0001445305-25-000142.md) | not reported | [(0.38)](/filings/0001445305-26-000045.md) | [(0.35)](/filings/0001445305-26-000060.md) | [0.05](/filings/0001445305-25-000142.md) | not reported | [0.33](/filings/0001445305-26-000045.md) | [0.24](/filings/0001445305-26-000060.md) |
| Basic EPS | $ per share | [(1.04)](/filings/0001445305-24-000143.md) | not reported | [(0.21)](/filings/0001445305-25-000091.md) | [(0.32)](/filings/0001445305-25-000125.md) | [(0.31)](/filings/0001445305-25-000142.md) | not reported | [(0.38)](/filings/0001445305-26-000045.md) | [(0.35)](/filings/0001445305-26-000060.md) | [0.05](/filings/0001445305-25-000142.md) | not reported | [0.33](/filings/0001445305-26-000045.md) | [0.24](/filings/0001445305-26-000060.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [405](/filings/0001445305-24-000143.md) | [256](/filings/0001445305-26-000016.md) | [296](/filings/0001445305-25-000091.md) | [268](/filings/0001445305-25-000125.md) | [248](/filings/0001445305-25-000142.md) | [302](/filings/0001445305-26-000016.md) | [242](/filings/0001445305-26-000045.md) | [284](/filings/0001445305-26-000060.md) | [316](/filings/0001445305-25-000142.md) | [339](/filings/0001445305-26-000060.md) | [334](/filings/0001445305-26-000045.md) | [252](/filings/0001445305-26-000060.md) |
| Current assets | $m | [947](/filings/0001445305-23-000166.md) | [1,009](/filings/0001445305-25-000034.md) | [997](/filings/0001445305-24-000071.md) | [932](/filings/0001445305-24-000107.md) | [989](/filings/0001445305-24-000143.md) | [1,048](/filings/0001445305-26-000016.md) | [974](/filings/0001445305-25-000091.md) | [1,023](/filings/0001445305-25-000125.md) | [1,092](/filings/0001445305-25-000142.md) | [1,162](/filings/0001445305-26-000060.md) | [1,108](/filings/0001445305-26-000045.md) | [1,064](/filings/0001445305-26-000060.md) |
| Total assets | $m | [1,149](/filings/0001445305-23-000166.md) | [1,219](/filings/0001445305-25-000034.md) | [1,202](/filings/0001445305-24-000071.md) | [1,243](/filings/0001445305-24-000107.md) | [1,302](/filings/0001445305-24-000143.md) | [1,368](/filings/0001445305-26-000016.md) | [1,294](/filings/0001445305-25-000091.md) | [1,346](/filings/0001445305-25-000125.md) | [1,411](/filings/0001445305-25-000142.md) | [1,494](/filings/0001445305-26-000060.md) | [1,425](/filings/0001445305-26-000045.md) | [1,374](/filings/0001445305-26-000060.md) |
| Current liabilities | $m | [438](/filings/0001445305-23-000166.md) | [485](/filings/0001445305-25-000034.md) | [467](/filings/0001445305-24-000071.md) | [506](/filings/0001445305-24-000107.md) | [539](/filings/0001445305-24-000143.md) | [592](/filings/0001445305-26-000016.md) | [547](/filings/0001445305-25-000091.md) | [662](/filings/0001445305-25-000125.md) | [692](/filings/0001445305-25-000142.md) | [742](/filings/0001445305-26-000060.md) | [686](/filings/0001445305-26-000045.md) | [723](/filings/0001445305-26-000060.md) |
| Total liabilities | $m | [1,263](/filings/0001445305-23-000166.md) | [1,308](/filings/0001445305-25-000034.md) | [1,285](/filings/0001445305-24-000071.md) | [1,320](/filings/0001445305-24-000107.md) | [1,353](/filings/0001445305-24-000143.md) | [1,410](/filings/0001445305-26-000016.md) | [1,369](/filings/0001445305-25-000091.md) | [1,412](/filings/0001445305-25-000125.md) | [1,448](/filings/0001445305-25-000142.md) | [1,499](/filings/0001445305-26-000060.md) | [1,438](/filings/0001445305-26-000045.md) | [1,472](/filings/0001445305-26-000060.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(114)](/filings/0001445305-24-000143.md) | [(89.4)](/filings/0001445305-26-000016.md) | [(83.2)](/filings/0001445305-25-000142.md) | [(77.7)](/filings/0001445305-25-000142.md) | [(50.8)](/filings/0001445305-25-000142.md) | [(41.7)](/filings/0001445305-26-000060.md) | [(75.7)](/filings/0001445305-26-000060.md) | [(66.5)](/filings/0001445305-26-000060.md) | [(36.9)](/filings/0001445305-25-000142.md) | [(5.4)](/filings/0001445305-26-000060.md) | [(12.6)](/filings/0001445305-26-000060.md) | [(97.1)](/filings/0001445305-26-000060.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.0](/filings/0001445305-24-000143.md) | [24.3 d](/filings/0001445305-26-000016.md) | [24.8](/filings/0001445305-25-000091.md) | [(0.0)](/filings/0001445305-25-000125.md) | [18.9](/filings/0001445305-25-000142.md) | [44.0 d](/filings/0001445305-26-000016.md) | [(7.4)](/filings/0001445305-26-000045.md) | [50.3](/filings/0001445305-26-000060.md) | [46.2](/filings/0001445305-25-000142.md) | [51.0 d](/filings/0001445305-26-000016.md) | [26.5](/filings/0001445305-26-000045.md) | [78.3](/filings/0001445305-26-000060.md) |
| Capital expenditure | $m | [0.9](/filings/0001445305-24-000143.md) | [0.4 d](/filings/0001445305-26-000016.md) | [0.2](/filings/0001445305-25-000091.md) | [0.1](/filings/0001445305-25-000125.md) | [0.2](/filings/0001445305-25-000142.md) | [0.8 d](/filings/0001445305-26-000016.md) | [0.8](/filings/0001445305-26-000045.md) | [1.0](/filings/0001445305-26-000060.md) | [0.1](/filings/0001445305-25-000142.md) | [0.2 d](/filings/0001445305-26-000016.md) | [0.7](/filings/0001445305-26-000045.md) | [0.3](/filings/0001445305-26-000060.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001445305-25-000091.md) | [0.0](/filings/0001445305-25-000125.md) | [0.0](/filings/0001445305-25-000142.md) | [0.0 d](/filings/0001445305-26-000016.md) | [40.1](/filings/0001445305-26-000045.md) | [10.0](/filings/0001445305-26-000060.md) | [10.0](/filings/0001445305-25-000142.md) | [11.5 d](/filings/0001445305-26-000016.md) | [50.0](/filings/0001445305-26-000045.md) | [123](/filings/0001445305-26-000060.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [53.1](/filings/0001445305-23-000166.md) | [53.7](/filings/0001445305-24-000071.md) | [54.0](/filings/0001445305-24-000107.md) | [54.3](/filings/0001445305-24-000143.md) | [54.9](/filings/0001445305-25-000091.md) | [55.2](/filings/0001445305-25-000125.md) | [55.6](/filings/0001445305-25-000142.md) | [56.2](/filings/0001445305-26-000045.md) | [56.1](/filings/0001445305-26-000060.md) | [58.2](/filings/0001445305-25-000142.md) | [58.4](/filings/0001445305-26-000045.md) | [56.1](/filings/0001445305-26-000060.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.